Cellumed Co., Ltd. announced that it expects to receive KRW 24.2199888 billion in funding from Free Telecom Co., Ltd. and other investors
January 29, 2021
Share
Cellumed Co., Ltd. (KOSDAQ:A049180) announced a private placement of 8,649,996 common shares at an issue price of KRW 2,800 per share for gross proceeds of KRW 24,219,988,800 on January 29, 2021. The transaction will include participation from returning investor Free Telecom Co., Ltd. for 3,571,428 shares, Mot Companion 11 Private Equity Partnership for 1,071,428 shares, Kang Myung-hee for 78,571 shares, Choi Ji Hee for 214,285 shares, Jeongah Lee for 107,142 shares, Jinyeol Kim for 35,714 shares and other investors. The transaction was approved by board of directors. The securities are issued through third-party allocation increase method. The shares have a hold period of one year post issuance. The payment date is February 8, 2021.
CELLUMED CO., LTD., formerly Korea Bone Bank CO., LTD, is a Korea-based company engaged in the manufacture and sale of medical equipment and biosimilars. The Companyâs products consist of allografts for tissue repair; bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration; biosimilars, such as bone morphogenetic protein 2 (BMP2) reagents and others, as well as medical devices, such as spinal fixation systems, joint replacements and navigation systems. The Company sells its products within domestic market and to overseas markets.
CELLUMED CO.,LTD. 
